Kenvue is the world's largest pure-play consumer health company by revenue, generating $15.1 billion in net sales in fiscal year 2025. Separated from Johnson & Johnson, the company markets a portfolio of brands — including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec — across three segments: Self Care, Skin Health and Beauty, and Essential Health, in more than 165 countries.
The company operates globally across North America, APAC, EMEA, and Latin America, leveraging precision marketing, e-commerce, and digital capabilities alongside healthcare professional engagement. As of the filing date, Kenvue had entered into a merger agreement with Kimberly-Clark Corporation announced November 2, 2025, and has been executing its Vue Forward restructuring program to drive cost savings and operational efficiencies post-separation from J&J.
Self Care 42% · Essential Health 31% · Skin Health And Beauty 27%
business segments · FY2025 (ended Dec 2025) · share of tagged segment revenue (10-K XBRL, as filed)
